Clinical consequences of heterozygosity for autosomal-recessive diseases.
Heterozygotes of autosomal-recessive diseases can often be recognized by special heterozygote tests, since enzyme activities are normally reduced in comparison with the normal homozygote state. In Drosophila, the majority of recessive lethal mutations shows a reduction of fitness in heterozygotes, whereas in a strong minority fitness of heterozygotes is increased. This review will be devoted to a consideration of the extent to which heterozygotes for a wide variety of nominally recessive diseases are subject either to an increased liability for common diseases or slight shifts of behavioral characteristics. The available evidence has been collected and will be discussed in three steps: Most studies are available for phenylketonuria. For this group of diseases, a slight reduction of average--especially verbal--I.Q. in heterozygotes has been reported together with signs of a slightly increased cerebral irritability, a possible slight increase of risk for mental disease, and an increase of blood phenylalanine levels in stress situations. The PKU example is used to discuss methodological problems involved in such studies. Other conditions for which relevant deviations in heterozygotes are possible or even likely include among others lipid storage diseases, microcephaly, myoclonus epilepsy, Wilson's disease, galaktokinase deficiency, homocystinuria, recessive myotonia and ataxia- teleangiectasia (increased cancer risk). Since heterozygotes for autosomal recessive diseases are common, it is possible that an appreciable fraction of "multifactorial" genetic liabilities for common, "constitutional" or mental disease might simply be due to heterozygosity for genes whose homozygous affects are already well known. By the same token, much of the "normal" genetic variability influencing cognitive performance (I.Q.)--especially in the lower range--and personality characteristics could also be caused by recessive genes in the heterozygous state.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations / Q000150:complications*; D025063:Chromosome Disorders; D005260:Female; D005693:Galactosemias / Q000150:complications; D005808:Genes, Recessive; D006579:Heterozygote; D006712:Homocystinuria / Q000150:complications; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008607:Intellectual Disability / Q000209:etiology; D008064:Lipidoses / Q000150:complications; D008297:Male; D008661:Metabolism, Inborn Errors / Q000150:complications*; D008831:Microcephaly / Q000150:complications / Q000235:genetics; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D010661:Phenylketonurias / Q000150:complications; D011247:Pregnancy; D011248:Pregnancy Complications / Q000209:etiology; D011602:Psychophysiologic Disorders / Q000209:etiology; D011618:Psychotic Disorders / Q000209:etiology